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Abstract 
Diabetes mellitus risk is increased by prolonged usage of antidepressants (ADs). Although 
various mechanisms are suggested for their diabetogenic potential, whether a direct effect of 
ADs on pancreatic β-cells is involved is unclear. We examined this idea for three ADs: 
paroxetine, clomipramine and, with particular emphasis, fluoxetine, on insulin secretion, 
mitochondrial function, cellular bioenergetics, KATP channel activity and caspase activity in 
murine and human cell-line models of pancreatic β-cells. Metabolic assays showed that these 
ADs decreased the redox, oxidative respiration and energetic potential of β-cells in a time and 
concentration dependent manner at concentrations (100 nM) well within their plasma therapeutic 
window. These effects were related to inhibition of mitochondrial complex I and III activity. 
Consistent with impaired mitochondrial function, lactate output was increased and insulin 
secretion decreased. Neither fluoxetine, antimycin nor rotenone could reactivate KATP channel 
activity blocked by glucose unlike the mitochondrial uncoupler, FCCP. Chronic, but not acute, 
AD increased oxidative stress and activated caspases, 3, 8 and 9. To conclude, paroxetine, 
clomipramine and fluoxetine were all found to be cytotoxic at therapeutic concentrations on 
pancreatic beta-cells; an action suggested to arise by inhibition of mitochondrial bioenergetics, 
oxidative stress and induction of apoptosis. These actions may help explain the diabetogenic 
potential of these ADs in humans. 
 
Keywords: Antidepressant, Diabetes mellitus, beta-cell, mitochondria, cytotoxicity, fluoxetine. 
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Introduction 
Antidepressants (ADs) play a key role in treating depression as well as other psychiatric 
disorders including anxiety and obsessive-compulsive disorders. However, clinical studies 
indicate that the tricyclic antidepressant (TCA) and serotonin selective reuptake inhibitor (SSRI) 
classes of AD are particularly associated with increased risks of hyperglycaemia and type 2 
diabetes mellitus (T2D) (Lustman et al., 1997; Rubin et al., 2008; Brown et al., 2008; Derijks et 
al., 2008; Andersohn et al., 2009; Kivimäki et al., 2010; Khoza et al., 2011). Although weight 
gain is a common side effect of AD usage (Uguz et al., 2015) and a risk factor for T2D 
(Andersohn et al., 2009; Kivimäki et al., 2010;), when weight is controlled for, ADs still increase 
T2D risk (Rubin et al., 2008; Pan et al., 2012).  
The effects of ADs on glucose homeostasis have been widely studied in rodents. The SSRI 
fluoxetine when administered acutely produces hyperglycaemia without hyperinsulinaemia 
(Yamada et al., 1999; Gomez et al., 2001), actions suggestive of a direct inhibition of insulin 
secretion. Similar trends are observed with clomipramine, a TCA, which also produces acute 
hyperglycaemia without hyperinsulinaemia in rodents (Sugimoto et al., 2003; Gomez et al., 
2001) as well as in humans (Lustman et al., 1997; McIntyre et al., 2006). In murine models, 
intraperitoneal administration of fluoxetine or clomipramine produces maximal hyperglycaemia 
within the first 30-90 minutes of injection (Yamada et al., 1999; Sugimoto et al., 2003; Gomez et 
al., 2001); observations that also indicate a direct action of these drugs on the β-cell, an idea 
further supported by their ability to inhibit insulin secretion from isolated pancreatic β-cells 
(Antoine et al., 2004; Cataldo et al., 2015). 
The mechanism of glucose stimulus-secretion coupling of insulin from the pancreatic β-cell is 
well understood, with a key role played by oxidative metabolism (Ashcroft et al., 1994; 
Maechler 2002). Clearly, any compound that interferes with mitochondrial bioenergetics and 
oxidative metabolism will impair insulin secretion; for example the mitochondrial Complex I 
inhibitor rotenone (MacDonald & Fahien, 1990; Zhou et al., 1999), Complex III inhibitor 
antimycin (Meglasson et al., 1987; MacDonald & Fahien, 1990), F0F1ATPase inhibitor 
oligomycin (Zhou et al., 1999; Ortsäter et al., 2002) and protonophore uncoupler FCCP 
(MacDonald & Fahien, 1990; Ortsäter et al., 2002) all act to achieve this.  
The ADs, amitriptyline, amoxapine, citalopram, clomipramine and fluoxetine have all been 
shown to cause mitochondrial dysfunction in other cell systems (Weinbach et al., 1986; Eto et 
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al., 1985; Souza et al., 1994; Xia et al., 1999; Curti et al., 1999; Chan et al., 2005). Where such 
events can culminate in oxidative stress and induction of apoptosis (Abdel-Razaq et al., 2011; Li 
et al., 2012).  
Mitochondria have key roles in the function of many other cell types, in particular those with a 
high energetic demand, for example sensory cells, neurons, skeletal and cardiac muscle. Why 
reports of adverse effects of chronic AD usage only appear for pancreatic β-cell function and not 
that of other tissue suggests that the mitochondria of the β-cell may be unique in its sensitivity to 
these classes of drugs. Indeed the predicted side effects of mitochondrial dysfunction in other 
cell types, whose function depends heavily on this organelle function: impaired vision, hearing 
loss, cardiac failure and skeletal muscle weakness, are not normally associated with AD usage 
(Joint Formulary Committee., 2016). 
Although mitochondria have key roles in many cell types, whether the diabetogenic effect of 
ADs is indeed mediated by action of these drugs on this organelle in pancreatic beta-cells has not 
been thoroughly explored. In this study, the ability of three ADs: paroxetine, fluoxetine and 
clomipramine, with particular emphasis on fluoxetine, to disrupt mitochondrial function, impair 
bioenergetics and inhibit insulin secretion of native and cell-line models of murine pancreatic β-
cells was investigated. In addition we explored both the effect of chronic actions of these drugs 
in order to mimic their long term usage, as well as their acute actions at higher concentrations in 
an attempt to mimic overdose and drug-drug interaction situations. 
 
Material and Methods 
Cells 
Unless stated otherwise, cells of the mouse pancreatic β-cell line MIN6 were employed 
(Miyazaki et al 1990). The MIN6 cell line is a well-established, time honored, model for the 
study of pancreatic β-cell function (Miyazaki et al., 1990; Ishihara et al., 1993; Daunt et al., 
2006; Cataldo et al., 2015). The main advantage of a cell line for pancreatic β-cell research is 
that it large numbers of phenotypically homogenous cells are available which are devoid of 
paracrine and neuroendocrine effects that arise from interaction with the other endocrine and 
neuronal cell types that reside within the pancreatic islet (Ishihara et al., 1993). Although MIN6 
have been reported to contain and secrete other pancreatic endocrine hormones, these cells still 
remain primarily β-cell in function (Nakashima et al., 2009). Cells were grown, and the chronic 
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experiments performed, in Dulbecco’s modified Eagle’s medium (DMEM) which contained 25 
mM glucose and was supplemented with: 2 mM L-glutamine, 10% fetal calf serum, 50 µM 2-
mercaptoethanol and 25 mM HEPES. In this study cells from passage numbers 35-42 were used. 
Some experiments were repeated with the human pancreatic beta-cell line, 1.1B4 (McCluskey et 
al., 2011). These cells were maintained and handled using the same protocols as for MIN6 
For validation in native tissue we used β-cells both from and within mouse islets of Langerhans. 
Pancreatic islets were isolated from the pancreata of male 30-35g CD1 mice as previously 
described (Daunt et al., 2006). Animals were kept under conditions and methods used that 
complied with local University rules approved by the UK government home office.  
 
Chronic studies 
Measurement of cell viability with MTT 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay relies on 
cellular reduction of the MTT substrate to produce a blue formazan product. As such it is a facile 
indicator of cell viability that results from the product of cell number and redox status (Elmorsy 
et al., 2014). The MTT assay was employed in accord with the manufacturer’s protocol 
(CellTiter 96 Non-Radioactive Cell Proliferation Assay; Promega, UK). Cells were incubated for 
4, 24, 48 or 72 hours in the presence of ADs or vehicle. In one set of experiments, this assay was 
repeated in the presence of 10 mM reduced glutathione (GSH) with a concentration of AD that 
inhibited MTT reduction by ~ 50% after 24 hours incubation (Elmorsy et al., 2014). 
To account for inter-experimental variation between well cell densities, MTT absorbance values 
are expressed as a percent of that measured for its respective vehicle control (defined as 100%). 
For all chronic assays, each experiment was performed in triplicate (technical repeat) with the 
average value considered as a single biological repeat. 
 
Intracellular ATP content 
As a direct measure of bioenergetic potential, intracellular ATP was measured as previously 
described (Elmorsy and Smith, 2015). Data was corrected for background luminescence by 
subtraction of the values measured in media alone. ATP levels are represented as a percentage 
measured in their respective vehicle control.  
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Insulin secretion 
For this and all subsequent chronic AD incubation assays, cells at confluence were washed twice 
with PBS and incubated for 24 hrs in DMEM with ADs or vehicle. To maximize effect detection, 
concentrations of ADs were chosen that inhibited MTT reduction/ATP production by ~ 50% 
after 24 hours incubation. 
To measure insulin secretion, the media was removed and the cells washed with PBS. Cells were 
then incubated for 15 minutes in serum free DMEM (25 mM glucose) absent of AD. This was 
removed for insulin assay and the cells measured for total insulin content. Insulin was measured 
by ELISA (Crystal Chem, Downers Grove, IL, USA) with secretion normalized to total insulin 
content. 
 
Lactate production 
To measure lactate in the chronic experiments the supernatant was collected and assayed by kit 
in accord with the manufacturer’s instructions (Biovision, Mountain View, CA). Lactate 
production was normalized to cell number, estimated with a heamocytometer, and expressed as a 
percentage of lactate produced with the vehicle control.  
 
Mitochondrial complex activity 
The effect of ADs on MIN6 cells mitochondrial complexes I and III were assessed as previously 
described (Elmorsy and Smith, 2015). To maximize event detection, concentrations of ADs were 
chosen that inhibited MTT reduction/ATP production by ~ 50% after 24 hours incubation. 
 
Oxidative stress 
The 3,7-dichlorodihydrofluorescein diacetate (DCFDA) assay was used to detect reactive oxygen 
species (ROS) and was performed following the protocol of Elmorsy et al  (2014). For a positive 
control 1 µM Antimycin A was added for 30 minutes, this blocks Complex III and generates of 
ROS. Non-stained cells were used for the blank and were subtracted from the data to correct for 
background luminescence.  
 
Caspase activity 
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To determine if the ADs, may induce apoptosis we evaluated the activities of caspases 3, 8 and 9 
after treatment with the ADs for 24 hrs. These were determined using a BD ApoAlert caspase 
fluorescent assay kits (Clontech Laboratories, Palo Alto, CA).  
 
Acute studies 
Unless stated otherwise, acute experiments were performed in a HEPES-buffered Hanks solution 
which contained (in mM):  138 NaCl, 4.2 NaHCO3, 1.2 NaH2PO4, 5.6 KCl, 1.2 MgCl2, 2.6 
CaCl2, 10 HEPES (pH 7.4 with NaOH) and 0.01 % fatty acid free BSA. 
 
Mitochondrial respiratory rate: O2 consumption 
The rate of O2 consumption (OCR) of MIN6 and 1.1B4 cell suspensions were measured 
polarographically with a redox over potential of -0.625 V using Clark Oxygen Electrodes (Rank 
Brothers, Bottisham, UK) as described previously (Daunt et al., 2006). The background O2 
consumption by the electrode was corrected for by subtraction of the OCR measured after the 
addition of 6 mM Na azide which blocks Complex IV and mitochondrial respiration. Results 
obtained with the N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD) and ascorbate electron 
shuttle system (ASB; Duchen et al., 1993; Daunt et al., 2006) were corrected for autoxidation of 
ascorbate via subtraction of the OCR obtained with ascorbate in the absence of cells: (0.3 nmol 
min-1 in 1 ml chamber volume).  To improve the statistical power for the substrate experiments, 
data was pooled from both control, and AD experiments, which resulted in different n numbers 
as indicated. 
 
Real time lactate production  
The rate of lactate production of MIN6 and 1.1B4 cell suspensions was measured simultaneously 
in conjunction with OCR. The appearance of lactate in the media was measured 
polarographically with Sarissa Lactate enzyme Electrodes according to the manufacturer’s 
protocol (Sarissa Biomedical Ltd Coventry, UK). The potential of the lactate electrode was set at 
+500 mV relative to a Ag/AgCl reference electrode (DriRef, WPI). At this potential the electrode 
oxidises H202, the product of lactate oxidation by lactate oxidase immobilised on the surface of a 
carbon fibre electrode; the resultant electrical curret is a stoichiometric measure of lactate 
concentration. Electrode calibration was performed with known concentrations of lactate and 
Page 7 of 39 Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
was linear up to ~800 µM (Sarissa Biomedical Ltd).  The lactate output of the cells was 
calculated after subtraction of the linear background leak current of the electrode measured in the 
absence of the acid (-1.38 nmol min-1 in 4 ml chamber volume). Compounds were confirmed as 
not to interfere with the electrode by protocol repetition in the absence of cells.  
 
Mitochondrial membrane potential  
The mitochondrial membrane potential, ∆Ψmit, was monitored with Rhodamine-123 (Rh-123) 
similar to that described previously (Daunt et al., 2006). Only cells that responded to glucose 
with a decrease in fluorescence and an increase to the protonophore FCCP (carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone) were chosen for quantitative analysis. Regions of interest 
(ROI) were drawn around cells, corrected for background fluorescence by subtraction, and the 
average ROI fluorescence intensity calculated. ROIs were recorded for both single cells and cell 
clusters within each visual field. Only cells that responded to glucose (hyperpolarization of 
∆Ψmit) were used for analysis. Image analysis was performed with custom scripts written in 
Labtalk (ORIGIN Ver, 6.0, OriginLab Corporation, MA USA). 
 
Patch-clamp studies of KATP channel activity 
As an indicator of sub-membrane ATP concentrations KATP channel activity was measured the 
with cell-attached patch-clamp technique as previously described (Ashcroft et al. 1988; Smith et 
al., 2001). Cells were bathed in a high potassium solution, nominally Ca2+ free, to 
electrochemically clamp the cell membrane potential (Vm) to 0 mV. The pipette potential, Vp, 
was held at + 70 mV to clamp the trans-patch membrane potential to -70 mV : (Vm – Vp). The 
pipette solution contained (in mM): 140 KCl, CaCl2 2.6, MgCl2 1.2, and HEPES 10 (pH 7.4 with 
NaOH). 100 µM tetraethyl ammonium was added to block voltage-gated K+ channels. 
Patch pipettes, resistances between 2-4 MΩ, were drawn from GC150TF capillary glass 
(Harvard Instruments), coated with dental wax (Kerr) and fire polished before use. Currents were 
measured using an Axopatch 1D patch clamp amplifier (Molecular Devices). The zero-current 
potential of the pipette was adjusted with the pipette in the bath just before seal establishment. 
No corrections have been made for liquid junction potentials (<4 mV).  Currents were low pass 
filtered at 2 kHz (–3db, 8 pole Bessel) and digitized at 10 kHz using PClamp 9.3 (Axon 
Instruments, Foster City, USA). Single-channel data were analyzed with half-amplitude 
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threshold techniques as implemented in Clampfit Ver. 10.6 (Axon Instruments, Foster City, 
USA). Channel activity, NPo, was recorded for 3 minute periods. These experiments were 
performed at 21-23 ºC a temperature at which glucose metabolism (Dawson et al., 1986) and its 
ability to block KATP channels  activity (Ashcroft et al., 1988; Smith et al; 2001) in  beta-cells is 
maintained, albeit slower than at 37 ºC. 
Mitochondrial superoxide 
To measure mitochondrial ROS and oxidative stress after acute AD incubation the fluorescent 
dye MitoSOXTM was employed in accord with the manufacturer’s instructions (ThermoFisher 
Scientific, Waltham MA USA). Cells cultured in 6-well plates to confluence were incubated in 
the dark with 5 µM MitoSOX reagent for 10 min at 37°C. Cells were then washed three times 
with PBS and incubated in Hanks solution with drugs for 120 min at 37°C. DMSO was used as 
the vehicle control, 1 µM antimycin A as the positive control and unstained cells for blank. Cells 
were then washed again with PBS and the dye excited at 510 nm. The emission at 580 nm was 
captured by fluorescence microscopy. After subtraction of the blank, the mean value of five 
random images from each well was taken as single sample. Velocity software (Ver. 6.3.1.0, 
Perkin Elmer Inc.) was used to analyze the fluorescent intensity of individual cells and clusters.  
 
Statistical analysis 
Statistical analysis and curve fitting was performed using Graphpad PRISM version 7.01 (San 
Diego, California USA). Data distributions were tested for normality with the D'Agostino & 
Pearson omnibus normality test and the appropriate statistical test used as given in the text. Inter-
experimental variation within the assay are either indicated by plots of raw values or the 
coefficient of variation, CV.  
The concentration-response relationships for the actions of ADs were quantified by fitting the 
assay data with equation 1:  Y    =   (100 - pedestal) / (1 + ( [AD] / IC50 )
h ) 
Where Y is the % of control (taken as 100%), pedestal is the minimum value for Y, h is the slope 
index, [AD] is the concentration of antidepressant and IC50 the concentration of drug that 
produces half-maximal inhibition. All the data generated was confirmed to best fit with a single 
rather than a two site binding model by the comparison method of Akaike’s Information Criteria 
(Graphpad PRISM).  
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The relationship between incubation time and IC50 was quantified by fitting the data with the 
empirical equation 2:  IC50, t= (IC50, t=0 - plateau) x exp (-K x t) + plateau  
Where IC50, t is IC50 at time t in hours, IC50, t=0 is the IC50 at time 0, plateau is the asymptotic value 
of IC50 and K is the rate constant (hours
-1). For the majority of the acute fluoxetine studies its 
IC50, t=0 value was used:  30 µM. 
Data are given in text as the mean ± SEM or median with 5 to 95% confidence intervals (C.I.), 
with n the number of individual determinations as appropriate. Statistical significance is defined 
as P <0.05. In graphics, P <0.05 is flagged as *, P <0.01  as **, P <0.001  as *** and P <0.0001  
as ****. Statistical tests are stated in the text and figure legends where appropriate. 
 
Results 
Chronic studies 
The ability of MIN6 to reduce MTT was maintained up to 72 hours, the longest period used (Fig. 
1A); in control cells there was no change in MTT reduction with time (Pearson r = 0.79, -0.71-1 
95% C.I; p=0.21), indicative of little cell replication over this time frame. Inter-experimental 
variation was small and ranged between 2.2 to 4.7 % (n = 9). Figs. 1B-D illustrates that 
paroxetine, fluoxetine and clomipramine inhibited the ability of MIN6 to reduce MTT in a time 
and concentration manner. Equation 1 was best fit to the data with IC50 and pedestal values given 
in Figs. 1E and F (h ~ 0.5). The maximum amount of block, as indicated by the decrease in 
pedestal, significantly increased with incubation time for both paroxetine (F test, p<0.005) and 
clomipramine (F test, p<0.0001) but not fluoxetine (Fig. 1F). Only the IC50 value for fluoxetine 
showed a significant change in magnitude with time of incubation (F test, p<0.0001; Figs. 1E) 
and was described by equation 2 with an IC50, t=0  of 33 µM (12 to 53,  95% C.I.), a plateau of 4.7 
µM (0 to 9.5,  95% C.I.) and a K of 0.1 hours-1  (0 to 2.8 , 95% C.I.). Fig. 1G demonstrates that a 
significant block of MTT reduction occurred with all three ADs at 100 nM, the lowest 
concentration used at all incubation times (One sample t test relative to vehicle control). Fig. 1H 
illustrates that co-incubation with 10 mM GSH partially reversed the inhibition of MTT 
reduction produced by the ADs.  
 
Fig. 2 shows that intracellular ATP production, like MTT reduction, was inhibited in a 
concentration-dependent manner after 24 hour exposure to AD. Inter-experimental variation 
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ranged from 1.7% CV for control up to 1.8 % CV in the presence of fluoxetine (n = 9). Equation 
1 was readily fit to the data with the same IC50’s given in Fig. 2D. For each AD tested no 
significant difference (ANOVA) was found between the IC50 for MTT and ATP; data when 
combined with the fact that cell density (Fig 3F ) did not change suggests that MTT is measuring 
redox status and not viability. All three ADs decreased the activity of both complex I and III 
(Fig. 2E and D; One sample t test relative to control). Inter-experimental variation as indicated 
by the CV ranged from 5% for control up to 18 % for Complex III in the presence of 
clomipramine (n = 3). 
 
Since these ADs decreased the activities of Complexes I and III, and also impaired the ability of 
MIN6 cells to reduce MTT and produce ATP, we investigated whether the drugs could affect 
glycolysis via measurement of their lactate output as well as generate ROS. Figs. 3A and B 
illustrate that paroxetine, fluoxetine and clomipramine all significantly increased lactate output 
and ROS when normalized to their respective controls (One sample t-test relative to 100%). 
However, a slightly different picture was observed when inter-plate variability was not 
controlled for and raw data was used instead (Figs. 3C &D), with significant effects only 
observed for fluoxetine when compared to its respective control (ANOVA with Dunnett’s).  
 
A prior 24 hour incubation in paroxetine and fluoxetine, at concentrations estimated to produce ~ 
50% inhibition of MTT reduction/ATP production, significantly decreased the ability of the 
MIN6 cells to secrete insulin (Fig. 3E, One sample t-test relative to control: 100%), however this 
treatment did not affect cell density (Fig. 3F). Similar conditions significantly increased the 
activity of caspases 3, 8 and 9 (Fig.3G) 
 
Acute studies 
As it is not readily possible to measure cellular redox potential via MTT reduction or cellular 
bioenergetics via ATP production over incubation times of minutes, these parameters were 
monitored instead by the rate of respiration (OCR) and mitochondrial membrane potential, 
∆ψmit, respectively (Duchen et al., 1993). Acute actions of these drugs are in keeping with 
accidental drug overdose, loading dosage or short term drug-drug interactions. 
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MIN6 suspensions consumed O2 (OCR) at a rate commensurate with cell density at 1.3±0.7 
nmoles 106 cells-1 min-1 (n = 112). Addition of 10 mM glucose produced a ~1.4 fold increase in 
OCR to 1.7±0.8 nmols 10
6 cells-1 min-1 (n = 112), subsequent addition of fluoxetine significantly 
decreased OCR (Figs. 4A-C). This effect was concentration-dependent with an IC50 of 230 µM 
(139 to 397, 95% C.I.) and h of 1.1 (0.6 to 1.6, 95% C.I; Fig. 4D solid line). After only 10 
minutes incubation, 3 µM was the lowest concentration of fluoxetine to have a significant effect 
on OCR (Kruskal-Wallis, Dunn’s multiple comparison test). Similar observations were made in 
the human beta-cell line 1.1B4 with an IC50 for fluoxetine of 232 µM (53 to 102, 95% C.I.) and h 
of 0.8 (0.4 to 1.2, 95% C.I; Fig. 4D solid line). The apparent potency of the SSRI to inhibit OCR 
in MIN6 was increased in 100 nM FCCP (F-test, P <0.04; Fig. 4C), with an IC50 of 97 µM (81-
117, 95% C.I.; data not shown) and h of 1.9 (0.9-2.8, 95% C.I). Acutely applied paroxetine failed 
to affect OCR even up to 100 µM, the highest concentration tested (data not shown) whereas 
clomipramine inhibited OCR with an IC50 of 284 µM (319-372, 95% C.I.) and h of 1.5 (0.87-2, 
95% C.I.) with 30 µM the lowest concentration that had a significant effect after 10 minute 
incubation (Kruskal-Wallis, Dunn’s multiple comparison test; data not shown).  
 
To confirm that the acute effect of fluoxetine on O2 consumption was not unique to cell lines, its 
effect on mouse pancreatic islets was tested. In the absence of exogenous substrate, pancreatic 
islets consumed O2 at 1.9±0.5 pmol O2 islet
-1 min-1 (n = 6). The addition of 20 mM glucose 
significantly increased OCR ~ 1.6 fold to 3.0±0.4 pmol O2 islet
-1 min-1 (p<0.05; ANOVA, 
Sidaks’s multiple comparison test; Fig. 4D); values akin to those previously reported (Daunt et 
al., 2006). Incubation in 100 µM fluoxetine for 10 minutes significantly inhibited OCR by 54 % 
to 1.6±0.3 pmol O2 islet
-1 min-1 (p<0.01; ANOVA, Sidaks’s multiple comparison test); a 
magnitude of block larger than that observed for MIN6 cells at the same drug concentration 
(33%; Unpaired t test with Welch's correction) and suggests an IC50 of ~100 µM for fluoxetine in 
the intact islet. 
To explore candidate target sites for the acute effect of fluoxetine on beta-cell metabolism, a 
range of substrates which feed in at different entry points of the catabolic pathway for glucose, 
stimulate OCR and elicit insulin secretion (Daunt et al., 2006) were tested for their susceptibility 
to inhibition by this SSRI. These were D-glyceralydehyde, methylpyruvate and α-
ketoisocaproate (all at 10 mM), and the electron shuttle TMPD/ascorbate (ASB) (Duchen et al., 
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2003).  Of these, only glyceraldehyde did not stimulate OCR relative to the osmotic control, 10 
mM 3-O-methyl glucose, (MOG; Fig. 5A; Kruskal-Wallis, Dunn’s multiple comparison test). 
Within 10 minutes of incubation, 30 µM fluoxetine inhibited respiration in the presence of all 
these substrates, except MOG where the block failed to reach significance, an effect regardless of 
the substrates’ ability to stimulate OCR (Fig. 5B; Mann Whitney test relative to respective 
vehicle control in each substrate).  
Although the magnitude of block produced by fluoxetine was unrelated to the change in OCR 
produced by substrate, it was positively correlated with the magnitude of basal OCR (Spearman 
r, Fig. 5C). This is exemplified in Fig. 5D, with the greatest inhibition produced by 30 µM 
fluoxetine was in cell suspensions with the largest basal OCR (Spearman r = 0.64, p<0.0001).  
This phenomenon was further explored with different glucose concentrations (Fig. 5E and F). 
Fig. 5E illustrates that a significant decrease in OCR occurred with fluoxetine (76% ± 2.6%; p< 
0.001  for all cases, paired Student’s t-test); an effect independent of glucose concentration and 
the OCR stimulated by the sugar (Spearman r = 0.04, p~0.5). Because the magnitude of the SSRI 
effect is independent of glucose concentration, when the effect of the drug is plotted as a % of 
the OCR measured in glucose, the inhibitory effect of the AD appears to be negatively correlated 
with the concentration of sugar (Fig. 5F; Spearman r = -0.96, p<0.01); with the SSRI appearing 
apparently less efficacious at the larger rates of respiration associated with higher glucose 
concentrations. 
 
Fig. 6 demonstrates that 10 mM glucose increased lactate production commensurate with an 
increase in OCR. Subsequent inhibition of OCR with 30 µM fluoxetine was associated with an 
increment in lactate output (Fig. 6A, B). The ability of fluoxetine to block OCR and stimulate 
lactate output was mimicked by 1 µM rotenone (Fig. 6C, D), with OCR blocked beyond basal in 
some cases. Fluoxetine at 30 µM also inhibited OCR and simulated lactate output in the human 
beta-cell line, 1.1B4 (Fig. 6E, F). These effects were significantly larger than those seen in MIN6 
cells,  a fact due to the greater rate of glucose utilization by1.14B. 
  
Fig. 7A shows that in the absence of exogenous substrate the mitochondrial membrane potential, 
∆Ψmit, as indicated by Rh123 fluorescence, was stable. Within one minute of 10 mM glucose 
addition, a sustained decrease in fluorescence occurred; an effect consistent with energization of 
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the mitochondria and polarization of ∆Ψmit associated with enhanced mitochondrial electron 
transport due to glucose metabolism (Duchen et al., 1993). Application of 2.5 µg ml-1 oligomycin 
decreased fluorescence consistent with an increase in ∆Ψmit due to the block of H+ leakage 
through the FO-F1-ATPase (Duchen et al., 1993). Subsequent addition of 1 µM antimycin 
increased Rh123 fluorescence; an observation consistent with the abolition of mitochondrial 
electron transport and collapse of ∆Ψmit since subsequent addition of 1 µM of the mitochondrial 
protonophore FCCP did not elicit a further increase in fluorescence (Fig. 7A). Fig. 7B shows that 
after energisation of ∆Ψmit with glucose, 30 µM fluoxetine increased Rh123 fluorescence; 
however, the depolarization of ∆Ψmit produced by fluoxetine was incomplete as demonstrated 
by the collapse of ∆Ψmit that occurred on the addition of 1 µM FCCP. Addition of 1 µM 
rotenone, like antimycin A, depolarized ∆Ψmit, and prevented further dissipation of ∆Ψmit by 
30 µM fluoxetine and 1 µM FCCP (Fig. 7C). H2O, the vehicle for fluoxetine, did not affect 
Rh123 fluorescence, whereas 1 µM FCCP could still collapse ∆Ψmit (Fig. 7D). Since the 
absolute value of ∆Ψmit reflects a balance between its generation by electron transport and its 
dissipation, predominantly via FO-F1-ATPase activity (Duchen et al., 2003), the ability of an 
agent to depolarize ∆Ψmit can be due to either inhibition of its generation or/and potentiation of 
its dissipation. On the basis of the retained ability of fluoxetine to inhibit OCR in the presence of 
FCCP, we assumed the former and quantified the action of fluoxetine on ∆Ψmit by its initial rate 
of effect (∆Rh123; Fig. 7E). ∆Rh123 was positively associated with drug concentration (Pearson 
r = 0.972, p < 0.01), with 10 µM the lowest fluoxetine concentration deemed to have a 
significant effect (ANOVA, Dunnett’s post comparison test).  Although 30 µM fluoxetine 
depolarized ∆Ψmit relative to H2O, the vehicle control (p<0.01, Kruskal-Wallis Dunn’s multiple 
comparison test), the magnitude of this effect was unrelated to the extent by which glucose 
energized ∆Ψmit (Pearson p>0.3), nor did it reverse the effect of glucose on ∆Ψmit (Fig. 7F).  
 
Fig. 8 shows that 1 µM Antimycin A after 30 minutes, but not 30 µM fluoxetine after 120 
minutes, significantly increased ROS in MIN6 cells relative to vehicle control (DMSO; p<0.001, 
ANOVA Holm-Sidak). 
 
 
FCCP, but  not fluoxetine reactivates KATP channel activity 
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Fig. 9A show that in the absence of glucose, cell-attached patches displayed single-channel 
currents with biophysical metrics characteristic for KATP-channels: a single channel current 
amplitude (i) of 4.8 ± 0.1 pA, burst kinetics and  a mean open-channel dwell time of 2.2 ± 0.1 ms  
(n = 27-37; Ashcroft et al. 1988; Smith et al., 2001). Fig. 9A and 9B shows that addition of 10 
mM glucose significantly reduced NPo by 99% (42 to 0%, 95% C.I; p<0.0001 Wilcoxon Signed 
rank test, n = 46) relative to the perifusion control that was without effect (Wilcoxon Signed rank 
test, n = 10).  Fluoxetine (1-100 µM) failed to reactivate KATP channel activity blocked by 
glucose, even after 10 minutes the longest period tested (Figs. 9A, 9C). Although 1 µM rotenone, 
a mitochondrial toxin which mimics the metabolic effects of fluoxetine, nor 1 µM antimycin, 
failed to reactivate the channel, 100 nM FCCP did (Kruskal-Wallis; Fig 9A and 9C) confirmed 
by the subsequent abolition of activity with 20 µM tolbutamide, a potent selective inhibitor of 
this channel type (Smith et al., 2001).  
Discussion 
Antidepressants are cytotoxic to MIN6  
Since all three ADs decreased MTT reduction and the ability of the β-cells to maintain ATP 
levels with similar IC50s without affecting cell density suggest they act to impair redox status. 
Previous studies have demonstrated that fluoxetine (Caminada et al., 2006; Levkovitz et al., 
2005; Krishnan et al., 2008), clomipramine (Levkovitz et al., 2005; Abdel-Razaq et al., 2011) 
and paroxetine (Amit et al. 2009) inhibit cell metabolism with similar IC50 values to those we 
report. Although these IC50’s exceeded the upper therapeutic concentration, in our hands all three 
drugs produced cytotoxic effects at the therapeutically relevant concentration of 100 nM. Despite 
intra-islet concentrations for these drugs being unavailable, magnetic resonance spectroscopy of 
19F fluoxetine in the human brain reveals a 10-20 fold accumulation of fluoxetine relative to 
plasma after 6-12 months treatment (Karson et al 1993; Bolo 2000), Together, these findings 
help explain the diabetogenic risk associated with prolonged AD usage and exposure (Lustman 
et al., 1997; Rubin et al., 2008; Brown et al., 2008; Derijks et al., 2008; Andersohn et al., 2009; 
Kivimäki et al., 2010; Khoza et al., 2011). 
The effects of the ADs are not mediated by blockade of serotonin transport 
Fluoxetine and paroxetine are SSRIs, whereas clomipramine acts both as an SSRI and a 
noradrenaline re-uptake inhibitor. These drugs are thought to achieve their antidepressant 
therapeutic activity, in part, through blockade of the serotonin transporter (SERT) which 
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enhances serotonin (5-HT) concentrations in the brain to alleviate the symptoms of depression 
(Blier & El Mansari, 2013). Pancreatic β-cells secrete 5-HT which may exert autocrine effects 
(Bennet et al., 2015). However, an involvement of SERT for the cytotoxic effects of these ADs 
can be dismissed, since β-cells do not express the Slc64a gene that encodes for SERT nor do 
ADs affect the release of 5-HT from them (Cataldo et al., 2015) . 
 
Antidepressants impair β-cell mitochondrial function  
The IC50 for the inhibition of oxidative respiration by acute application of fluoxetine on intact β-
cells is comparable to that seen in isolated mitochondria from liver (~300 µM; Souza et al., 
1994) and brain (~150 µM; Curti et al., 1999) both for this drug and its metabolite norfluoxetine. 
Furthermore, Hroudová et al (2012) reports that fluoxetine inhibits Complex 1 and II with IC50’s 
of 86 and 266 µM respectively.  Other mitochondrial targets for fluoxetine are the F0Fl-ATPAse 
(Souza et al., 1994; Curti et al., 1999) and the voltage-dependent anion channel, VDAC (Nahon 
et al., 2005). However, neither of these proteins are likely targets since when the activity of F0Fl-
ATPAse was uncoupled from mitochondrial electron transport by FCCP, the IC50 for fluoxetine 
was not increased; whereas blockade of VDAC by fluoxetine is associated with an enhanced, not 
impaired, mitochondrial function (Nahon et al., 2005). 
The fact that the IC50 values obtained from the acute studies exceed the chronic values probably 
reflect a failure of the ADs to reach equilibrium over the short time periods employed.  This is 
particularly exemplified by fluoxetine whose affinity increased with incubation time with a half-
life of 6.9 hrs.  
 
Role of mitochondrial Complexes 
The observations that AD bioenergetic effects were not associated with changes in cell density is 
consistent with a decrease in cell oxidative respiration capacity; an idea supported by the loss of 
mitochondrial Complexes seen in other systems:  30% decrease in Complex IV in the β-cell line 
INS1E with 48 hour exposure to 1 µM fluoxetine (De Long et al., 2014); >20% decrease for all 
four Complexes in CHO cells after 18 hour incubation with >10 µM clomipramine (Abdel-Razaq 
et al., 2011). Moreover, at 1 µM the atypical AD bupropion, also associated with an increased 
risk of diabetes (Andersohn et al., 2009), impairs mitochondrial Complex IV function and insulin 
secretion in INS1E cells after a 48 hour exposure (Woynillowicz et al., 2012). Complex I and 
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complex III inhibition is considered the main source of ROS in cells (Ježek et al., 2005; Chen  et 
al., 2003). Such a process was demonstrated in our in our chronic but not acute studies, an effect 
also observed in INS1E cells when incubated with fluoxetine (De Long et al., 2014).These data 
suggest that maintained loss of mitochondrial Complex activity and ROS production only occurs 
with prolonged AD exposure; effects similar to thos observed in β-cells with exogenous H2O2 
(Li et al., 2009). 
 
Fluoxetine blocks basal β-cell lipid metabolism  
In the absence of exogenous substrate pancreatic β-cells respire primarily via beta-oxidation of 
endogenous lipids (Corkey et al., 1989) which involves FADH and Complex II/III. The 
observation that acute fluoxetine had an effect size that correlated with basal rather than 
stimulated respiration lends support to Complex II/III as an acute target for this AD; since 
inhibition of Complex II/III will prevent beta-oxidation of endogenous lipids and OCR. Indeed, 
fluoxetine partially mimics the antimycin inhibition of Complex II/III on ∆ψmit. A 
mitochondrial target for fluoxetine is supported by the increase in lactate production that occurs 
with this SSRI, a phenomenon like that produced by rotenone due to a failure of the beta-cell to 
oxidize NADH via Complex I which necessitates NADH recycling via increased lactate 
generation from pyruvate. 
 
Antidepressants decrease insulin secretion by MIN6 
The decrease in glucose-stimulated insulin secretion may be due to a combination of both 
oxidative stress and decreased ATP production. Pancreatic β-cells are characterized by a 
relatively weak expression of superoxide dismutase, catalase and glutathione peroxidase 
(Grankvist et al., 1996; Lenzen et al., 1996); enzymes that metabolize and neutralize ROS. 
Consequently, exposure to oxidative as is the case here, may be sufficient to impair glucose-
stimulated insulin secretion (Maechler et al., 1999; Sakai et al., 2003; Li et al., 2009). The 
finding that co-incubation with GSH partially reversed the ability of AD to inhibit MTT 
reduction is consistent with this notion. The associated suppression of intracellular ATP due to 
bioenergetic disruption will also act to decrease insulin secretion as it is the major coupling 
factor for glucose-induced insulin secretion (Ashcroft et al., 1994; Maechler 2002). The ability of 
Page 17 of 39 Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ADs to impair beta-cell bioenergetics readily explains their ability to induce hyperglycaemia 
without hyperinsulinaemia in vivo (Yamada et al., 1999; Gomez et al., 2001). 
 
Fluoxetine fails to activate KATP channels in MIN6 
Plasma-membrane KATP channel activity was blocked by glucose and solely reactivated by 
FCCP; however, they were not reactivated by fluoxetine, rotenone or antimycin. This is probably 
because these compounds failed to impair mitochondrial ATP production sufficiently to 
reactivate KATP; unlike FCCP which uncouples respiration and leads to cellular consumption of 
ATP via reverse mode F0F1-ATPase activity (Rustenbeck et al., 1997). Rotenone and antimycin 
are well-known to inhibit insulin secretion independently of KATP channels due to the intimate 
relationship between mitochondrial metabolism and secretory steps distal to membrane ionic 
events (MacDonald & Fahien, 1990; Ortsäter et al., 2002), and as we show here fluoxetine, too 
can also impair mitochondrial respiration acutely which explains its acute hyperglycemic affects 
in-vitro (Antoine et al., 2004; Cataldo et al., 2015) and in-vivo (Yamada et al., 1999; Gomez et 
al., 2001). 
 
Suitability of MIN6 as a metabolic model of native pancreatic beta-cells 
We found that glucose stimulated MIN6 OCR 1.4 fold that of basal, close to that of 1.6 observed 
for mouse islets. Furthermore, the MIN6 cell OCR of 1.7 nmol 106 cells-1 min-1 in glucose is 
similar to that of 3 nmol O2 10
6 cells-1 min-1 of the mouse islets preparations (Daunt et al., 2006). 
Moreover,  the 2.6 nmol min-1 106 cell lactate from MIN6 in 10 mM glucose is similar to that for 
rat islets: 2.0 nmol min-1 106 cell (Sener et al., 1976). Furthermore, we estimate a lactate to OCR 
ratio of 3.6±1 (n = 8) for MIN6, a ratio like that reported for rat β-cells (2.4; Sener et al., 1976). 
Together, these data support MIN6 cells as a suitable metabolic model of native β-cells in which 
to study mitochondrial function.  
 
Conclusion and clinical implications 
We found that paroxetine, clomipramine and fluoxetine were cytotoxic to mouse pancreatic β-
cells, an effect dependent on concentration and duration of exposure. Importantly, adverse 
metabolic effects were seen at chronic AD concentrations of 100 nM; a value less than the 
median therapeutic concentration for most dosage regimens (Reis et al., 2009). Moreover, as the 
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plasma concentration for these ADs are well established to be related to dose (Reis et al., 2009), 
a daily fluoxetine dose of 80 mg can yield steady state plasma concentrations >2 µM (Lundmark 
et al., 2001), a concentration sufficient to disrupt beta-cell mitochondrial bioenergetics. 
Obviously, plasma concentrations during loading and drug-drug interactions concentrations may 
transiently surpass 2 µM. Why these ADs seem to have adverse clinical affects manifested 
predominantly by pancreatic β-cell dysfunction probably relates to the poor antioxidant abilities 
of this cell type, since they were mitigated in part by GSH. Overall, our data suggests that a 
direct cytotoxic effect of these ADs on pancreatic β-cells may contribute to the diabetogenic 
potential of antidepressants. 
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Figure Captions 
Fig. 1 Antidepressants inhibit MTT reduction. A) Absorbance of MTT reduction measured 
(arbitrary units, A.U.) in a murine pancreatic β cell-line (MIN6) under control conditions as a 
function of time. Each point is a triplicate average from a separate experiment (n = 9). B-D) 
Concentration-effect relationships for the effect of paroxetine (B), fluoxetine (C) and 
clomipramine (D) on the reduction of MTT measured after 4 different times of incubation as 
indicated: , 4 hrs; , 24 hrs; , 48 hrs; ,  72 hrs. Data are mean ± SEM as a percentage of 
values measured under control conditions (n = 9 in all cases). Solid lines are fits of equation 1 to 
the data with the parameter values given in E) and F). E-F) Time courses of IC50 and pedestal 
respectively for the inhibition of MTT reduction by the drugs indicated: , PAR, paroxetine; , 
FLX, fluoxetine; , CLM, clomipramine.  For E) data is given as mean ± 95% C.I., for F) data 
is mean ± SEM (n = 9). Solid line in E is a fit of equation 2 to the FLX data with parameter 
values given in the text. G) Time course for inhibition of MTT reduction by 100 nM AD taken 
from B, C and D. Data mean ± SEM (n = 9). The effect of all three ADs are positively correlated 
with time (Pearson, r > 0.98 and P< 0.05 for all cases). H) Effect of ADs in the absence (open 
bars) and presence (filled bars) of 10 µM GSH. Cells were incubated for 24 hours in 55 µM 
paroxetine (PAR), 29 µM fluoxetine (FLX) or 44 µM clomipramine (CLM); concentrations that 
inhibit MTT reduction by ~ 50% over this time period. Data mean ± SEM (n = 9). Statistical 
significance determined by Paired t-test. 
 
 
Fig. 2 Antidepressants inhibit ATP production and mitochondrial Complex activity. a-d) 
Comparison of the concentration-effect relationships for three ADs on MTT and ATP levels in 
MIN6 cells after 24 hours of incubation. Effect of paroxetine (A), fluoxetine (B) and 
clomipramine (C). Data are the mean ± SEM as a percentage of control values (n = 9 in all 
cases). Solid lines are fits of equation 1 to the data with the IC50s given in D). D) Comparison of 
the IC50’s for the inhibition of MTT reduction () and ATP production () by the drugs 
indicated: PAR, paroxetine; FLX, fluoxetine; CLM, clomipramine.  Data given as mean ± 95% 
C.I. Data is from 9 experiments in each case. E-F) Comparison between the effects of 55 µM 
paroxetine (PAR), 29 µM fluoxetine (FLX) and 44 µM clomipramine (CLM) on the activity of 
mitochondrial Complex I activity (E) and Complex III activity (F) after 24 hr incubation. Data 
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shown as mean ± SEM (n = 3). ). Statistical significance determined by One sample t-test with a 
theoretical mean of 100%. 
 
 
Fig. 3 Antidepressants inhibit insulin secretion increase lactate output and promote 
reactive species generation.  Cells were incubated for 24 hours in 55 µM paroxetine (PAR), 30 
µM fluoxetine (FLX) or 45 µM clomipramine (CLM). Data are shown either as raw values or as 
a percentage of values measured under control conditions: for lactate production (A & C 
respectively) and generation of reactive oxygen species (ROS) (B & D respectively).  E) Insulin 
secretion stimulated in response to 25 mM glucose for a 15 minutes period post AD treatment. F) 
Cell count after 24 hr incubation at the concentrations of AD given above. Results are expressed 
as mean± SEM (n = 3 for each situation). G) Caspase activity after 24 hr incubation at the 
concentrations of AD given above. Results are expressed as mean ± SEM (n = 3-9 for each 
situation). Open bars, caspase 3; light bars, caspase 8, dark bars, caspase 9. Statistical 
significance for A, B and G was determined by One way ANOVA with Dunnett's multiple 
comparisons test relative to control for all others by One sample t-test with a theoretical mean of 
100%. 
 
Fig. 4. Fluoxetine inhibits oxygen consumption. A) Representative records of oxygen 
concentration for three different suspensions of MIN6 cells showing stimulation of oxygen 
consumption (respiration) by 10 mM glucose and the subsequent inhibition by 10, 30 and 100 
µM fluoxetine. B) Fluoxetine concentration-response relationship for OCR inhibition as a 
percentage of that measured in 10 mM glucose for MIN6 () and human 1.1B4 () cell lines. 
Data are means ± S.E.M (n= 6 - 29). See text for details of fitted lines.  Statistical significance is 
relative to vehicle control determined via Kruskal-Wallis for MIN6. C) Percentage change in 
OCR relative to that measured in the absence of exogenous substrate (basal) under the conditions 
indicated: Glu, 10 mM glucose and then 100 µM fluoxetine, FLX (Wilcoxon signed rank test, n 
= 17); Glu, 10 mM glucose, then 100 nM FCCP followed by 100 µM fluoxetine, FFLX 
(Friedman test; n = 10). D) OCR of 6 different pancreatic islet preparations measured under the 
conditions indicated: Bas, basal in the absence of exogenous substrate; Glu, in 20 mM glucose; 
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FLX, 20 mM glucose and 100 µM fluoxetine. Statistical significance determined by 1-way 
ANOVA with Sidak’s multiple comparison test. 
 
Fig. 5. Substrate independent effects of fluoxetine on respiration. A) Oxygen consumption 
rate (OCR) stimulated by methyl-O-glucose (MOG, n = 42), D-glucose (GLU, n = 71), D-
glyceraldehyde (GLY, n = 34), methylpyruvate (MP, n = 30) and α-ketoisocaproate (KIC, n = 
33), all at 10 mM, and by tetramethyl-p-phenylenediamine/ascorbate (ASB; n = 45). Data are 
box and whisker (Tukey). Statistical significance is relative to MOG determined via Kruskal-
Wallis with Dunn’s multiple comparison test. B) Percentage inhibition of OCR by 30 µM 
fluoxetine in the presence of the same substrates as in A (n = 8-25). Statistical significance is 
relative to respective water controls via Mann-Whitney. Data are box and whisker (Tukey). C) 
Spearman r values and associated probabilities for the correlation between magnitude of 
inhibition produced by 30 µM fluoxetine and basal OCR (open columns) or OCR stimulated by 
the substrates indicated (closed columns): MOG (3-O-methylglucose, n = 8),  GLU (glucose, n = 
25), GLY (DL-glyceraldehyde, n = 10); MP (methyl-pyruvate, n = 8), KIC (α-ketoisocaproic 
acid, n = 10) all at 10 mM and ASB (TMPD/ascorbate, n = 10). D) Correlation between the 
decline in OCR produced by 30 µM fluoxetine (FLX) and basal OCR (n = 24).  E) Glucose 
concentration-response relationships for OCR relative to basal in the absence () and presence 
() of 100 µM fluoxetine, (n = 5-8). Data are means ± SEM. Note the similar difference 
between the two sets of data for each glucose concentration. F) Glucose concentration-response 
relationships for the % inhibition of OCR by 100 µM fluoxetine. Data are means ± SEM and are 
calculated from that shown E. 
Fig. 6. Acute fluoxetine stimulates lactate production. Simultaneously measured changes in 
oxygen consumption rate (∆OCR) and lactate production (∆Lactate) compared to those 
measured in the absence of exogenous substrate (basal). A-B) Effect of 10 mM glucose (Glu), 
and then 30 µM fluoxetine (FLX) in the continued presence of the sugar on OCR (A) and lactate 
output (B) from the same 5 sets of experiments (matched by symbol). C-D) Effects of 10 mM 
glucose (Glu), and 1 µM rotenone (Rot) in the continued presence of the sugar on OCR (C) and 
lactate output (D) from the same 5 sets of experiments (matched by symbol). Note that rotenone 
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inhibits OCR beyond that measured in basal to give a negative value. E-F) Comparison of the 
effects of 30 µM fluoxetine in the presence of 10 mM glucose (Glu) on OCR (E) and lactate 
output (F) for MIN6 (MIN6F; n = 5) and 1.1B4 (11B4; n = 5). Statistical significance is via 
Mann-Whitney. 
Fig. 7. Rh123 fluorescence as a measure of the mitochondrial membrane potential, ∆Ψmit. 
Effects of 10 mM glucose and drugs as indicated on ∆Ψmit, in MIN6 cells. A-D) ∆Ψmit is 
represented by the change in Rh-123 fluorescence relative to that measured in the absence of the 
sugar (100%). Compounds were applied for the duration of the bars. Records are representative 
of at least 3 different experiments for each condition and are formed from the average of at least 
7 ROIs. A) Effects of 10 mM glucose, 2.5 µg ml-1 oligomycin (Olig), 1 µM antimycin A (AntA) 
and 1 µM FCCP (FC). B) The effects of 10 mM glucose, 30 µM fluoxetine (FLX) followed by 1 
µM FCCP (FC). C) Effects of 10 mM glucose, 1 µM rotenone (Rot) 30 µM fluoxetine (FLX) and 
1 µM FCCP (FC). D) The effect of water then 1 µM FCCP (FC) in the presence of 10 mM 
glucose. E) Concentration-response relationship for the initial rate of Rh123 fluorescence 
increase (∆Rh123) produced by fluoxetine (). Data are the means ±S.E.M. (n = 3-9). Statistical 
significance is vie ANOVA with Dunnett’s post comparison test relative to water control. F) Box 
and whisker (Tukey) comparison of Rh123 fluorescence relative to basal (100%); GLU, effect of 
glucose (n = 184); FLX, plus 30 µM fluoxetine (n = 156); H20, water control (n = 28). Data is 
from at least 5 independent preparations in each case, where n is the total number of ROI 
measured for each condition. Statistical significance is via Kruskal-Wallis with Dunn’s multiple 
comparison test. 
Fig. 8. MitoSOX fluorescence as a measure of mitochondrial superoxide generation. A-C) 
Representative images of MIN6 cells in DMSO (A), 30 µM fluoxetine (B) and 1 µM antimycin 
(C) all for 1 hr from the same experimental run. Red fluorescence demonstrates the detection of 
the superoxide anion by the MitoSOX dye. Scale bar 30 µm, all images at 50% brightness. D) 
Amount of superoxide generated, measured in arbitrary fluorescence units under the conditions 
indicated: Ctrl, basal conditions (n = 8); DMSO, vehicle control for fluoxetine and antimycin (n 
= 5); FLX, 30 µM fluoxetine (n = 7); ANTA, 1 µM antimycin (n = 9). 
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Fig. 9. Cell-attached study of KATP channel activity A) Representative records of KATP 
channel activity measured from the same MIN6 cell under the successive conditions indicated. 
Dotted line is the zero-current level, openings are downward. B) Box and whisker (Tukey) 
comparison of KATP channel activity (NPo) normalised to that measured in zero glucose; Ctrl, 
perifusion control (n = 10), Glucose, 10 mM Glucose (n = 46). C) Box and whisker (Tukey) 
comparison of KATP channel activity reactivated, as a % of that blocked by 10 mM glucose, with 
the treatments indicated; H2O, water vehicle control (n = 8); 1F, 1 µM fluoxetine (n = 7); 3F, 3 
µM fluoxetine (n = 5); 10F, 10 µM fluoxetine (n = 5); 30F, 30 µM fluoxetine (n = 8); 100F, 100 
µM fluoxetine (n = 5); Rot, 1 µM rotenone (n = 6); FCCP, 100 nM FCCP (n = 16);   Tol, 100 
nM FCCP + 20 µM tolbutamide (n = 9); Ant, 1 µM antimycin (n = 4). 
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Fig. 1 Antidepressants inhibit MTT reduction. A) Absorbance of MTT reduction measured (arbitrary units, 
A.U.) in a murine pancreatic β cell-line (MIN6) under control conditions as a function of time. Each point is a 
triplicate average from a separate experiment (n = 9). B-D) Concentration-effect relationships for the effect 
of paroxetine (B), fluoxetine (C) and clomipramine (D) on the reduction of MTT measured after 4 different 
times of incubation as indicated:●, 4 hrs; ■, 24 hrs; △, 48 hrs; ▽,  72 hrs. Data are mean ± SEM as a 
percentage of values measured under control conditions (n = 9 in all cases). Solid lines are fits of equation 1 
to the data with the parameter values given in E) and F). E-F) Time courses of IC50 and pedestal 
respectively for the inhibition of MTT reduction by the drugs indicated: ●, PAR, paroxetine; ■, FLX, 
fluoxetine; △, CLM, clomipramine.  For E) data is given as mean ± 95% C.I., for F) data is mean ± SEM (n = 
9). Solid line in E is a fit of equation 2 to the FLX data with parameter values given in the text. G) Time 
course for inhibition of MTT reduction by 100 nM AD taken from B, C and D. Data mean ± SEM (n = 9). The 
effect of all three ADs are positively correlated with time (Pearson, r > 0.98 and P< 0.05 for all cases). H) 
Effect of ADs in the absence (open bars) and presence (filled bars) of 10 µM GSH. Cells were incubated for 
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24 hours in 55 µM paroxetine (PAR), 29 µM fluoxetine (FLX) or 44 µM clomipramine (CLM); concentrations 
that inhibit MTT reduction by ~ 50% over this time period. Data mean ± SEM (n = 9). Statistical significance 
determined by Paired t-test.  
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Fig. 2 Antidepressants inhibit ATP production and mitochondrial Complex activity. a-d) Comparison of the 
concentration-effect relationships for three ADs on MTT and ATP levels in MIN6 cells after 24 hours of 
incubation. Effect of paroxetine (A), fluoxetine (B) and clomipramine (C). Data are the mean ± SEM as a 
percentage of control values (n = 9 in all cases). Solid lines are fits of equation 1 to the data with the IC50s 
given in D). D) Comparison of the IC50’s for the inhibition of MTT reduction (●) and ATP production (■) by 
the drugs indicated: PAR, paroxetine; FLX, fluoxetine; CLM, clomipramine.  Data given as mean ± 95% C.I. 
Data is from 9 experiments in each case. E-F) Comparison between the effects of 55 µM paroxetine (PAR), 
29 µM fluoxetine (FLX) and 44 µM clomipramine (CLM) on the activity of mitochondrial Complex I activity 
(E) and Complex III activity (F) after 24 hr incubation. Data shown as mean ± SEM (n = 3). Statistical 
significance determined by One sample t-test with a theoretical mean of 100%.  
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Fig. 3 Antidepressants inhibit insulin secretion increase lactate output and promote reactive species 
generation.  Cells were incubated for 24 hours in 55 µM paroxetine (PAR), 30 µM fluoxetine (FLX) or 45 µM 
clomipramine (CLM). Data are shown either as raw values or as a percentage of values measured under 
control conditions: for lactate production (A & C respectively) and generation of reactive oxygen species 
(ROS) (B & D respectively).  E) Insulin secretion stimulated in response to 25 mM glucose for a 15 minutes 
period post AD treatment. F) Cell count after 24 hr incubation at the concentrations of AD given above. 
Results are expressed as mean± SEM (n = 3 for each situation). G) Caspase activity after 24 hr incubation 
at the concentrations of AD given above. Results are expressed as mean ± SEM (n = 3-9 for each situation). 
Open bars, caspase 3; light bars, caspase 8, dark bars, caspase 9. Statistical significance for A, B and G was 
determined by One way ANOVA with Dunnett's multiple comparisons test relative to control for all others by 
One sample t-test with a theoretical mean of 100%.  
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Fig. 4. Fluoxetine inhibits oxygen consumption. A) Representative records of oxygen concentration for three 
different suspensions of MIN6 cells showing stimulation of oxygen consumption (respiration) by 10 mM 
glucose and the subsequent inhibition by 10, 30 and 100 µM fluoxetine. B) Fluoxetine concentration-
response relationship for OCR inhibition as a percentage of that measured in 10 mM glucose for MIN6 (●) 
and human 1.1B4 (○) cell lines. Data are means ± S.E.M (n= 6 - 29). See text for details of fitted 
lines.  Statistical significance is relative to vehicle control determined via Kruskal-Wallis for MIN6. C) 
Percentage change in OCR relative to that measured in the absence of exogenous substrate (basal) under 
the conditions indicated: Glu, 10 mM glucose and then 100 µM fluoxetine, FLX (Wilcoxon signed rank test, n 
= 17); Glu, 10 mM glucose, then 100 nM FCCP followed by 100 µM fluoxetine, FFLX (Friedman test; n = 10). 
D) OCR of 6 different pancreatic islet preparations measured under the conditions indicated: Bas, basal in 
the absence of exogenous substrate; Glu, in 20 mM glucose; FLX, 20 mM glucose and 100 µM fluoxetine. 
Statistical significance determined by 1-way ANOVA with Sidak’s multiple comparison test.  
 
151x109mm (300 x 300 DPI)  
 
 
Page 36 of 39Toxicological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
Fig. 5. Substrate independent effects of fluoxetine on respiration. A) Oxygen consumption rate (OCR) 
stimulated by methyl-O-glucose (MOG, n = 42), D-glucose (GLU, n = 71), D-glyceraldehyde (GLY, n = 34), 
methylpyruvate (MP, n = 30) and α-ketoisocaproate (KIC, n = 33), all at 10 mM, and by tetramethyl-p-
phenylenediamine/ascorbate (ASB; n = 45). Data are box and whisker (Tukey). Statistical significance is 
relative to MOG determined via Kruskal-Wallis with Dunn’s multiple comparison test. B) Percentage 
inhibition of OCR by 30 µM fluoxetine in the presence of the same substrates as in A (n = 8-25). Statistical 
significance is relative to respective water controls via Mann-Whitney. Data are box and whisker (Tukey). C) 
Spearman r values and associated probabilities for the correlation between magnitude of inhibition produced 
by 30 µM fluoxetine and basal OCR (open columns) or OCR stimulated by the substrates indicated (closed 
columns): MOG (3-O-methylglucose, n = 8),  GLU (glucose, n = 25), GLY (DL-glyceraldehyde, n = 10); MP 
(methyl-pyruvate, n = 8), KIC (α-ketoisocaproic acid, n = 10) all at 10 mM and ASB (TMPD/ascorbate, n = 
10). D) Correlation between the decline in OCR produced by 30 µM fluoxetine (FLX) and basal OCR (n = 
24).  E) Glucose concentration-response relationships for OCR relative to basal in the absence (●) and 
presence (○) of 100 µM fluoxetine, (n = 5-8). Data are means ± SEM. Note the similar difference between 
the two sets of data for each glucose concentration. F) Glucose concentration-response relationships for the 
% inhibition of OCR by 100 µM fluoxetine. Data are means ± SEM and are calculated from that shown E.  
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Fig. 6. Acute fluoxetine stimulates lactate production. Simultaneously measured changes in oxygen 
consumption rate (∆OCR) and lactate production (∆Lactate) compared to those measured in the absence of 
exogenous substrate (basal). A-B) Effect of 10 mM glucose (Glu), and then 30 µM fluoxetine (FLX) in the 
continued presence of the sugar on OCR (A) and lactate output (B) from the same 5 sets of experiments 
(matched by symbol). C-D) Effects of 10 mM glucose (Glu), and 1 µM rotenone (Rot) in the continued 
presence of the sugar on OCR (C) and lactate output (D) from the same 5 sets of experiments (matched by 
symbol). Note that rotenone inhibits OCR beyond that measured in basal to give a negative value. E-F) 
Comparison of the effects of 30 µM fluoxetine in the presence of 10 mM glucose (Glu) on OCR (E) and 
lactate output (F) for MIN6 (MIN6F; n = 5) and 1.1B4 (11B4; n = 5). Statistical significance is via Mann-
Whitney.  
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Fig. 7. Rh123 fluorescence as a measure of the mitochondrial membrane potential, ∆Ψmit. Effects of 10 mM 
glucose and drugs as indicated on ∆Ψmit, in MIN6 cells. A-D) ∆Ψmit is represented by the change in Rh-123 
fluorescence relative to that measured in the absence of the sugar (100%). Compounds were applied for the 
duration of the bars. Records are representative of at least 3 different experiments for each condition and 
are formed from the average of at least 7 ROIs. A) Effects of 10 mM glucose, 2.5 µg ml-1 oligomycin (Olig), 
1 µM antimycin A (AntA) and 1 µM FCCP (FC). B) The effects of 10 mM glucose, 30 µM fluoxetine (FLX) 
followed by 1 µM FCCP (FC). C) Effects of 10 mM glucose, 1 µM rotenone (Rot) 30 µM fluoxetine (FLX) and 1 
µM FCCP (FC). D) The effect of water then 1 µM FCCP (FC) in the presence of 10 mM glucose. E) 
Concentration-response relationship for the initial rate of Rh123 fluorescence increase (∆Rh123) produced 
by fluoxetine (●). Data are the means ±S.E.M. (n = 3-9). Statistical significance is vie ANOVA with Dunnett’s 
post comparison test relative to water control. F) Box and whisker (Tukey) comparison of Rh123 
fluorescence relative to basal (100%); GLU, effect of glucose (n = 184); FLX, plus 30 µM fluoxetine (n = 
156); H20, water control (n = 28). Data is from at least 5 independent preparations in each case, where n is 
the total number of ROI measured for each condition. Statistical significance is via Kruskal-Wallis with 
Dunn’s multiple comparison test.  
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Fig. 8. MitoSOX fluorescence as a measure of mitochondrial superoxide generation. A-C) Representative 
images of MIN6 cells in DMSO (A), 30 µM fluoxetine (B) and 1 µM antimycin (C) all for 1 hr from the same 
experimental run. Red fluorescence demonstrates the detection of the superoxide anion by the MitoSOX dye. 
Scale bar 30 µm, all images at 50% brightness. D) Amount of superoxide generated, measured in arbitrary 
fluorescence units under the conditions indicated: Ctrl, basal conditions (n = 8); DMSO, vehicle control for 
fluoxetine and antimycin (n = 5); FLX, 30 µM fluoxetine (n = 7); ANTA, 1 µM antimycin (n = 9).  
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Fig. 9. Cell-attached study of KATP channel activity A) Representative records of KATP channel activity 
measured from the same MIN6 cell under the successive conditions indicated. Dotted line is the zero-current 
level, openings are downward. B) Box and whisker (Tukey) comparison of KATP channel activity (NPo) 
normalised to that measured in zero glucose; Ctrl, perifusion control (n = 10), Glucose, 10 mM Glucose (n = 
46). C) Box and whisker (Tukey) comparison of KATP channel activity reactivated, as a % of that blocked by 
10 mM glucose, with the treatments indicated; H2O, water vehicle control (n = 8); 1F, 1 µM fluoxetine (n = 
7); 3F, 3 µM fluoxetine (n = 5); 10F, 10 µM fluoxetine (n = 5); 30F, 30 µM fluoxetine (n = 8); 100F, 100 µM 
fluoxetine (n = 5); Rot, 1 µM rotenone (n = 6); FCCP, 100 nM FCCP (n = 16);   Tol, 100 nM FCCP + 20 µM 
tolbutamide (n = 9); Ant, 1 µM antimycin (n = 4).  
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